Breast Cancer

Quick Answer

Nuclear medicine's role in breast cancer is concentrated in locally advanced and metastatic disease: FDG-PET/CT stages and restages, detects distant metastases, and assesses treatment response, outperforming conventional imaging in higher-stage disease. Sentinel lymph-node biopsy (lymphoscintigraphy) is the standard for axillary staging in early clinically node-negative disease — not PET. F-18-FES (fluoroestradiol) PET images estrogen-receptor expression across all lesions to inform endocrine therapy.

Definition

Breast cancer is a malignant epithelial neoplasm of the breast, most commonly invasive carcinoma of no special type (ductal, IDC/NST) or invasive lobular carcinoma (ILC), preceded by in-situ disease (DCIS). It is biologically defined by receptor status — estrogen (ER), progesterone (PR), and HER2 — which drives both prognosis and therapy.

Synonyms

Invasive breast carcinoma; invasive ductal carcinoma (IDC / no special type); invasive lobular carcinoma (ILC); ductal carcinoma in situ (DCIS). Molecular/clinical subtypes: luminal A/B, HER2-enriched, and triple-negative/basal-like.

Epidemiology

Breast cancer is the most commonly diagnosed cancer in women and a leading cause of female cancer death. Incidence rises with age; risk is increased by family history / BRCA mutations, prolonged estrogen exposure (early menarche, late menopause, nulliparity, hormone therapy), dense breasts, obesity, alcohol, and prior chest radiation. Screening mammography shifts detection toward earlier stage.

Etiology & Risk Factors

• Genetic: BRCA1/2 (and TP53/Li-Fraumeni, PTEN/Cowden, PALB2, CHEK2, ATM); strong family history.
• Hormonal/reproductive: early menarche, late menopause, nulliparity/late first birth, menopausal hormone therapy.
• Other: dense breast tissue, obesity (postmenopausal), alcohol, prior thoracic radiation, and increasing age.

Pathophysiology

Breast cancer is largely hormone-driven in the luminal subtypes, with proliferation controlled by ER signaling — the rationale for endocrine therapy. HER2 (ERBB2) amplification drives a distinct aggressive-but-targetable subtype. Triple-negative disease lacks ER/PR/HER2 and behaves aggressively with a chemotherapy/immunotherapy paradigm. Metastatic tropism is characteristically to bone (often osteoblastic/mixed), lung, liver, and brain; lobular cancer has a distinctive pattern (serosal, GI, gynecologic, and diffuse marrow spread) and is frequently FDG-poor.

Genetics & Molecular Biology

• Receptor biomarkers: ER, PR, HER2, Ki-67 define subtype and therapy.
• Actionable alterations: BRCA1/2 (PARP inhibitors), PIK3CA (PI3K inhibitors), ESR1 mutations (acquired endocrine resistance), HER2-low status (antibody–drug conjugates).
• Genomic assays (Oncotype DX, MammaPrint) guide adjuvant chemotherapy in early ER-positive disease.
• Intrinsic subtypes (luminal A/B, HER2-enriched, basal) integrate this biology.

Histopathology

IDC/NST (most common) and ILC (single-file growth, E-cadherin loss, often multifocal and FDG-poor) are the dominant invasive types. DCIS is the non-invasive precursor. Special favorable types (tubular, mucinous) are frequently low-grade and FDG-low. Grade (Nottingham) and receptor IHC complete the pathologic picture.

Clinical Presentation

A painless breast mass, skin/nipple changes (retraction, discharge), or a screen-detected abnormality. Inflammatory breast cancer presents with erythema and peau d'orange (dermal lymphatic invasion). Axillary adenopathy may be the first sign. Metastatic disease presents with bone pain, or organ-specific symptoms.

Laboratory Findings

No routine diagnostic serum marker. CA 15-3 / CEA may be used to trend metastatic disease. Receptor testing (ER/PR/HER2) on tissue is mandatory; germline BRCA and tumor genomic testing guide therapy.

Imaging Findings by Modality

• Mammography: screening and diagnostic workhorse (masses, calcifications).
• Ultrasound: targeted evaluation and biopsy guidance; nodal assessment.
• MRI: high-risk screening, extent-of-disease, and problem-solving (especially ILC).
• FDG-PET/CT: locally advanced, metastatic, recurrent disease — staging, restaging, distant metastases, and response.
• FES-PET: whole-body ER phenotyping.
• Bone scan / NaF-PET: osseous metastases (bone scan traditional; PET more sensitive).
• Dedicated breast PET (PEM) / molecular breast imaging (Tc-99m-sestamibi): problem-solving in specific settings.

Radiopharmaceutical Uptake Mechanisms

FDG reflects glucose metabolism — high in high-grade/triple-negative and HER2 disease, but low in lobular, tubular, mucinous, and low-grade cancers. F-18-FES binds the estrogen receptor with uptake correlating to ER expression (hepatobiliary excretion limits hepatic-lesion assessment; recent ER-blocking drugs cause false negatives). Tc-99m-sestamibi accumulates by mitochondrial/perfusion mechanisms (molecular breast imaging). Bone diphosphonates mark osteoblastic reaction.

Typical PET Tracers

Typical SPECT Tracers

• Sentinel-node lymphoscintigraphy (Tc-99m-sulfur colloid / tilmanocept) — axillary staging in early disease.
• Tc-99m-sestamibi — molecular breast imaging / scintimammography.
• Tc-99m-MDP — bone-scan osseous staging.

Therapy Indications

• Local: breast-conserving surgery or mastectomy with sentinel-node biopsy (SLNB), plus radiotherapy as indicated.
• Systemic (by subtype): endocrine therapy ± CDK4/6 inhibitors (ER-positive), anti-HER2 antibodies/ADCs (HER2-positive/low), chemotherapy and immunotherapy (triple-negative), and PARP inhibitors (BRCA).
• Bone-directed agents (bisphosphonate/denosumab) for skeletal metastases and SRE prevention.

Theranostics

Breast cancer's principal "image-and-treat" pairing is FES → endocrine therapy: FES noninvasively confirms ER expression across all lesions (capturing heterogeneity a single biopsy misses) to select and stratify endocrine treatment. HER2 molecular imaging (⁸⁹Zr-trastuzumab) and HER2-targeted antibody–drug conjugates point toward a theranostic future, though radioligand therapy is not yet standard in breast cancer.

Differential Diagnosis (of breast/axillary FDG uptake)

• Fibroadenoma, post-biopsy/post-surgical inflammation, fat necrosis, and inflammatory/infectious change (mastitis) — benign FDG-avid mimics.
• Reactive axillary nodes (including post-vaccination) versus nodal metastasis.
• Physiologic lactational uptake.

Reporting Checklist

• State indication (advanced-disease staging / restaging / response) and correlate with receptor status.
• Report nodal, skeletal, visceral, and brain considerations (brain needs MRI).
• For FES: confirm ER-blocking drugs were held appropriately; note hepatobiliary excretion limiting hepatic lesions.
• Note the FDG-low histology caveat (lobular, tubular, mucinous, low-grade) when SUV is unexpectedly low.

Prognosis

Prognosis is driven by stage, grade, and receptor subtype: luminal A tends to be indolent; HER2-enriched and triple-negative are more aggressive (though HER2 disease is now highly treatable). Nodal status, tumor size, and genomic-assay risk refine adjuvant decisions. Metastatic disease is generally incurable but increasingly chronic, with survival strongly subtype-dependent.

Board facts at a glance

The high-yield discriminations, consolidated:

Board Pearls

FDG-PET/CT's value is in locally advanced, metastatic, and recurrent disease — it outperforms conventional imaging at higher stage — while the early clinically node-negative axilla is staged by sentinel-node biopsy (NSABP B-32), not PET. F-18-FES noninvasively maps estrogen-receptor expression across all lesions to guide endocrine therapy.

Invasive lobular carcinoma and low-grade/tubular/mucinous tumors are frequently FDG-poor — interpret a normal SUV cautiously and lean on MRI for extent.

FES pitfalls: recent ER-targeting therapy (tamoxifen/fulvestrant) blocks the receptor and causes false negatives — hold per protocol and mind timing — and intense hepatobiliary excretion makes FES unreliable for hepatic lesions. On FDG, watch benign avid mimics (fibroadenoma, post-biopsy change, mastitis) and reactive/post-vaccination axillary nodes.

Related Pages

• Tracer: FDG and F-18-FES (fluoroestradiol).
• Related studies: Lymphoscintigraphy & sentinel node (axillary staging).
• Pitfalls: Pearls, pitfalls & normal variants.

Figure / Diagram Suggestions

• A subtype matrix (ER/PR/HER2 → luminal A/B, HER2-enriched, TNBC) mapped to therapy and FDG avidity.
• FES mechanism cartoon: ER binding, whole-body phenotyping, and the ER-blocker false-negative.
• Sentinel-node vs FDG-PET decision by stage (early axilla vs advanced disease).

Common Pitfalls

• Sclerotic/osteoblastic bone metastases may be FDG-non-avid, while lytic marrow lesions are avid — FDG can under-call sclerotic-only osseous disease, so pair with bone scan/NaF-PET or CT.
• On post-therapy scans, new/denser sclerosis and transiently increased uptake can represent healing (flare), not progression — judge against later timepoints and CT morphology.
• Brown fat in supraclavicular, axillary, and paraspinal regions mimics nodal disease — recognize the symmetric CT-fat correlate.
• Physiologic breast parenchymal and lactational uptake is diffuse and often bilateral — do not mistake for malignancy.
• FDG brain uptake is physiologically high, so PET is unreliable for cerebral metastases — dedicated brain MRI is required.

Self-Check (Board-Style)